Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer:A Single Center Trial

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer:A Single Center Trial - Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer:A Single Center Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010232

Enrollment

Registered

2013-03-13

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic cancer

Interventions

Erlotinib Plus Gemcitabine Gemcitabine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with advanced pancreatic cancer

Exclusion criteria

Exclusion criteria: Patients with not advanced pancreatic cancer

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026